Monday, October 04, 2021 4:59:37 PM
As I stated here before, the FDA has fee reduction/elimination for small companies beginning their first drug approval process. CV Sciences qualifies in every category for fee elimination so they could begin clinical trials without initial fees of 3 million or more.
Just getting into clinical trials will do wonders for the share price. It's quite possible Duffy is leaving because he is no longer needed to cross this finish line... we may already be there.
Recent CVSI News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 09:06:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2024 02:17:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:54:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 01:28:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 01:10:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 02:36:49 PM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM